Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies

摘要: Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading antigenic editing, and means of activating both T B arms system been devised. Therapeutic vaccination monoclonal antibody therapy so far disappointing, because tumors prove adept at evasion from control. Dual targeting could well counteract evasion, provided that two targets are independent attacked simultaneously. This stage nearly but not quite reached in several forms immunotherapy, particularly B-cell cancers, although such treatment also carries hazards.